DalCor Pharmaceuticals: DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round

DalCor Pharmaceuticals announced the closing of the company's Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.